Harvard Bioscience Raises Full-Year Revenue Guidance on Strong Q2 Growth
Event summary
- Q2 2026 revenue grew 11% YoY to $22.7M, driven by strong demand in telemetry and cellular/molecular technology (CMT) products.
- Adjusted EBITDA for Q2 2026 was $1.7M, up from $1.5M in Q2 2025.
- Full-year revenue guidance raised to 3-5% YoY growth, up from previous expectations.
- Gross margin slightly impacted by mix shift due to higher-volume, lower-margin CMT products and geographic factors.
The big picture
Harvard Bioscience's strong Q2 performance reflects broader industry trends toward digital and molecular research tools. The company's ability to raise full-year guidance signals confidence in its commercial traction, particularly in high-growth areas like telemetry and CMT products. However, maintaining profitability amid product mix shifts will be critical as it scales operations globally.
What we're watching
- Product Mix Dynamics
- Whether the shift toward higher-volume, lower-margin CMT products will sustain gross margin pressures.
- Geographic Expansion
- The pace at which China and other international markets contribute to revenue growth.
- Operational Efficiency
- How ongoing cost discipline impacts adjusted EBITDA in the second half of 2026.
Related topics